Applications of solid-state NMR spectroscopy to pharmaceuticals

European Pharmaceutical Review

Volumn 18, Issue 1, 2013, Pages

  Munson, Eric ^a   Endowed, Patrick DeLuca ^a  

^a University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; QUANTITATIVE ANALYSIS; SOLID STATE NMR SPECTROSCOPY;

EID: 84877252013     PISSN: 13608606     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (23)

1. Tishmack PA, Bugay DE, Byrn SR 2003. Solid-state nuclear magnetic resonance spectroscopy -Pharmaceutical applications. Journal of Pharma -ceutical Sciences 92(3):441-474 (Pubitemid 36258961)
2. Harris RK 2007. Applications of solid-state NMR to pharmaceutical polymorphism and related matters. Journal of Pharmacy and Pharmacology 59(2):225-239 (Pubitemid 46203061)
3. Geppi M, Mollica G, Borsacchi S, Veracini CA 2008. Solid-state NMR studies of pharmaceutical systems. Applied Spectroscopy Reviews 43(3):202-302 (Pubitemid 351411554)
4. Vogt FG 2010. Evolution of solid-state NMR in pharmaceutical analysis. Future Medicinal Chemistry 2(6):915-921
5. Berendt RT, Sperger DM, Isbester PK, Munson EJ 2006. Solid-state NMR spectroscopy in pharmaceutical research and analysis. Trac-Trends in Analytical Chemistry 25(10):977-984 (Pubitemid 44666187)
6. Offerdahl TJ, Salsbury JS, Dong ZD, Grant DJW, Schroeder SA, Prakash I, Gorman EM, Barich DH, Munson EJ 2005. Quantitation of crystalline and amorphous forms of anhydrous neotame using C-13 CPMAS NMR spectroscopy. Journal of Pharmaceutical Sciences 94(12):2591-2605 (Pubitemid 43265384)
7. Harris RK 2006. NMR studies of organic polymorphs & solvates. Analyst 131(3):351-373
8. Gao P 1996. Determination of the composition of delavirdine mesylate polymorph and pseudo -polymorph mixtures using C-13 CP/MAS NMR. Pharmaceutical Research 13(7):1095-1104 (Pubitemid 26259014)
9. Wenslow RM 2002. F-19 solid-state NMR spectroscopic investigation of crystalline and amorphous forms of a selective muscarinic M-3 receptor antagonist, in both bulk and pharmaceutical dosage form samples. Drug Development and Industrial Pharmacy 28(5):555-561 (Pubitemid 34680555)
10. Lefort R, De Gusseme A, Willart JF, Danede F, Descamps M 2004. Solid state NMR and DSC methods for quantifying the amorphous content in solid dosage forms: an application to ball-milling of trehalose. Int J Pharm 280(1-2):209-219 (Pubitemid 38950917)
11. Farrer BT, Peresypkin A, Wenslow RM 2007. Quantitation of crystalline material within a liquid vehicle using H-1/F-19 CP/MAS NMR. Journal of Pharmaceutical Sciences 96(2):264-267 (Pubitemid 46363557)
12. Virtanen T, Maunu SL 2010. Quantitation of a polymorphic mixture of an active pharmaceutical ingredient with solid state C-13 CPMAS NMR spectroscopy. Int J Pharm 394(1-2):18-25
13. Zielinska-Pisklak M, Pisklak DM, Wawer I 2012. Application of C-13 CPMAS NMR for Qualitative and Quantitative Characterization of Carvedilol and its Commercial Formulations. Journal of Pharmaceutical Sciences 101(5):1763-1772
14. Kimura K, Hirayama F, Arima H, Uekama K 1999. Solidstate C-13 nuclear magnetic resonance spectroscopic study on amorphous solid complexes of tolbutamide with 2-hydroxypropyl-Alpha-And -beta-cyclodextrins. Pharmaceutical Research 16(11):1729-1734 (Pubitemid 29530406)
15. Forster A, Apperley D, Hempenstall J, Lancaster R, Rades T 2003. Investigation of the physical stability of amorphous drug and drug/polymer melts using variable temperature solid state NMR. Pharmazie 58(10):761-762 (Pubitemid 37328412)
16. Schachter DM, Xiong JC, Tirol GC 2004. Solid state NMR perspective of drug-polymer solid solutions: a model system based on poly(ethylene oxide). Int J Pharm 281(1-2):89-101 (Pubitemid 39024266)
17. Masuda K, Tabata S, Sakata Y, Hayase T, Yonemochi E, Terada K 2005. Comparison of molecular mobility in the glassy state between amorphous indomethacin and salicin based on spin-lattice relaxation times. Pharmaceutical Research 22(5):797-805 (Pubitemid 40768593)
18. Pham TN, Watson SA, Edwards AJ, Chavda M, Clawson JS, Strohmeier M, Vogt FG 2010. Analysis of Amorphous Solid Dispersions Using 2D Solid-State NMR and H-1 T-1 Relaxation Measurements. Molecular Pharmaceutics 7(5):1667-1691
19. Brus J, Urbanova M, Sedenkova I, Brusova H 2011. New perspectives of F-19 MAS NMR in the characterization of amorphous forms of atorvastatin in dosage formulations. Int J Pharm 409(1-2):62-74
20. Luthra SA, Utz M, Gorman EM, Pikal MJ, Munson EJ, Lubach JW 2012. Carbon-deuterium rotational-echo double-resonance NMR spectroscopy of lyophilized aspartame formulations. Journal of Pharmaceutical Sciences 101(1):283-290
21. Yoshioka S, Aso Y, Kojima S 1999. The effect of excipients on the molecular mobility of lyophilized formulations, as measured by glass transition temperature and NMR relaxation-based critical mobility temperature. Pharmaceutical Research 16(1):135-140 (Pubitemid 29047470)
22. Suihko EJ, Forbes RT, Apperley DC 2005. A solid-state NMR study of molecular mobility and phase separation in co-spraydried protein-sugar particles. European Journal of Pharmaceutical Sciences 25(1):105-112 (Pubitemid 40602200)
23. Wojnarowska Z, Grzybowska K, Adrjanowicz K, Kaminski K, Paluch M, Hawelek L, Wrzalik R, Dulski M, Sawicki W, Mazgalski J, Tukalska A, Bieg T 2010. Study of the Amorphous Glibenclamide Drug: Analysis of the Molecular Dynamics of Quenched and Cryomilled Material. Molecular Pharmaceutics 7(5):1692-1707